Technetium (99mTc) votumumab

Technetium (^99mTc) votumumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	tumor antigen CTAA16.88
Clinical data
ATC code	V09IA04 (WHO)
Legal status
Legal status	not marketed
Identifiers
CAS Number	148189-70-2^N
ChemSpider	none
UNII	63635D7SGF
^NY (what is this?)  (verify)

Technetium (^99mTc) votumumab (trade name HumaSPECT) is a human monoclonal antibody labelled with the radionuclide technetium-99m.^[1][2] It was developed for the detection of colorectal tumors, but has never been marketed.^[3]

The target of votumumab is CTAA16.88, a complex of cytokeratin polypeptides in the molecular weight range of 35 to 43 kDa, which is expressed in colorectal tumors.^[4]

References

1. "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (1). 1999.
2. Hendriks BS, Gaddy DF (2017). "Radiolabeled Antibody-Based Imaging in Clinical Oncology". In Olivier Jr KJ, Hurvitz SA (eds.). Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer. Hoboken, New Jersey: John Wiley & Sons. p. 441. ISBN 978-1-119-06084-0.
3. "Public Statement on HumaSPECT" (PDF). European Medicines Agency (EMA_. 23 February 2004. Archived from the original (PDF) on 2007-06-10. Non-renewal of the marketing authorisation in the European Union
4. "Summary of Product Characteristics for HumaSPECT" (PDF). European Medicines Agency (EMA).